Repligen Corporation · NASDAQ:RGEN
Repligen — Merger or Acquisition (October 2011)
5 slides from Repligen's merger presentation, Oct 28, 2011
Slide 1: Repligen Acquires Business of Novozymes Biopharma AB
Repligen Acquires Business of Novozymes Biopharma AB October 28, 2011 Exhibit 99.2
Slide 2: Slide 2
Slide 3: Four Major Products to Drive Growth
Four Major Products to Drive Growth Confidential Do Not Reproduce or Distribute Repligen Novozymes Attributes Native Protein A • Early blockbuster monoclonal antibodies for cancer • >1,000 ongoing trials support future growth Recombinant Protein A Recombinant Protein A • Newer monoclonals approved f
Slide 4: Chromatography Products - Opus™
Chromatography Products - Opus™ • Disposable products revolutionizing bio-manufacturing - Sales of $500M in fermentation - Minimal impact on purification • Opus™ pre-packed chromatography columns - Plastic, “plug and play” solution - Large scale columns launch in Q1 CY2012 - Clinical market opportun
Slide 5: Slide 5
Repligen — Merger or Acquisition (October 2011) on 6ix